» Articles » PMID: 33009011

A Taxonomy of Pragmatic Measures of HIV Preexposure Prophylaxis Use

Overview
Journal AIDS
Date 2020 Oct 3
PMID 33009011
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: As delivery of preexposure prophylaxis (PrEP) becomes an HIV prevention priority in the United States, standard, pragmatic measures of PrEP use are needed to compare and evaluate prevention implementation programs. By using readily available electronic health record data, we describe and compare measures of persistence and retention.

Design: Retrospective cohort.

Methods: Using electronic health record prescription data for patients at a large urban Federally Qualified Health Center from 2015 to 2019, we calculated measures of persistence and retention and compared them to pharmacy claims data, PrEP biomarkers, and HIV outcomes.

Results: Total PrEP time was 19.8 months on average. During this period, average adherence by medication prescription ratio (MRxR) was 89%; 77% of patients had an MRxR at least 85% and 90% have an MRxR at least 57%. Over the first 6 months, average proportion of days covered (PDC) at least 85% was 53% and PDC at least 57% was 57%. Prescription fill rates, based on claims data from a pharmacy partner, ranged from 45 to 60%. Using tenofovir-diphosphate as the gold standard, PDC had high sensitivity (97%) but low specificity (≤13%). As a measure of retention, over the first 6 months, 59% of patients had quarterly HIV tests.

Conclusion: Total PrEP time is useful measure of overall persistence, while PDC can assess persistence and adherence at a specific time point. Adherence by PDC is more conservative compared with MRxR; both will overestimate true adherence. Retention in care can be measured by quarterly HIV tests. Using consistent terminology and reporting timepoints and adherence thresholds will help reporting and comparing PrEP delivery programs.

Citing Articles

Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections Among Individuals Using HIV Preexposure Prophylaxis.

Traeger M, Leyden W, Volk J, Silverberg M, Horberg M, Davis T JAMA Intern Med. 2025; 185(3):273-281.

PMID: 39761062 PMC: 11877173. DOI: 10.1001/jamainternmed.2024.7186.


HIV preexposure prophylaxis treatment patterns in a national health plan population.

Rastegar J, Hu A, Chung L, Stevens L, Dixon S, Schwab P J Manag Care Spec Pharm. 2023; 29(12):1267-1274.

PMID: 38058138 PMC: 10776253. DOI: 10.18553/jmcp.2023.29.12.1267.


HIV Prevention and Care Among Black Cisgender Sexual Minority Men and Transgender Women: Protocol for an HIV Status-Neutral Cohort Study Using an Observational-Implementation Hybrid Approach.

Knox J, Dolotina B, Moline T, Matthews I, Durrell M, Hanson H JMIR Res Protoc. 2023; 12:e48548.

PMID: 38039075 PMC: 10724817. DOI: 10.2196/48548.


PrEP Persistence Support and Monitoring in Areas of High HIV Burden in the Midwestern United States.

McNulty M, Kerman J, Devlin S, Pyra M, Rusie L, Curoe K AIDS Educ Prev. 2023; 35(3):235-246.

PMID: 37410372 PMC: 10328557. DOI: 10.1521/aeap.2023.35.3.235.


Risk-based versus universal PrEP delivery during pregnancy: a cluster randomized trial in Western Kenya from 2018 to 2019.

Kinuthia J, Dettinger J, Stern J, Ngumbau N, Ochieng B, Gomez L J Int AIDS Soc. 2023; 26(2):e26061.

PMID: 36807505 PMC: 9939942. DOI: 10.1002/jia2.26061.


References
1.
Montgomery M, Oldenburg C, Nunn A, Mena L, Anderson P, Liegler T . Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. PLoS One. 2016; 11(6):e0157742. PMC: 4917105. DOI: 10.1371/journal.pone.0157742. View

2.
Siegler A, Mouhanna F, Mera Giler R, Weiss K, Pembleton E, Guest J . The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018; 28(12):841-849. PMC: 6286209. DOI: 10.1016/j.annepidem.2018.06.005. View

3.
Marcus J, Hurley L, Hare C, Nguyen D, Phengrasamy T, Silverberg M . Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016; 73(5):540-546. PMC: 5424697. DOI: 10.1097/QAI.0000000000001129. View

4.
Krakower D, Maloney K, Powell V, Levine K, Grasso C, Melbourne K . Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J Int AIDS Soc. 2019; 22(2):e25250. PMC: 6376610. DOI: 10.1002/jia2.25250. View

5.
Dombrowski J, Golden M, Barbee L, Khosropour C . Patient Disengagement From an HIV Preexposure Prophylaxis Program in a Sexually Transmitted Disease Clinic. Sex Transm Dis. 2018; 45(9):e62-e64. PMC: 6086745. DOI: 10.1097/OLQ.0000000000000823. View